UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
October 25, 2004
Date of Report (Date of earliest event reported)
CONNETICS CORPORATION
(Exact name of Registrant as specified in its charter)
| | | | | |
| Delaware | | 0-27406 | | 94-3173928 |
| |
| |
|
(State or Other Jurisdiction
of Incorporation) | | (Commission File No.) | | (IRS Employer
Identification No.) |
3290 West Bayshore Road, Palo Alto, California 94303
(Address of principal executive offices, including zip code)
(650) 843-2800
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 8.01. Other Events.
On October 25, 2004, Connetics Corporation (“Connetics”) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Connetics New Drug Application for Velac, with a filing date of August 23, 2004, and a user fee goal date of June 25, 2005. A copy of the Connetics press release regarding Velac is attached as Exhibit 99.1 and is incorporated by reference in this Item 8.01.
On October 25, 2004, Connetics also announced that the U.S. Food and Drug Administration (FDA) has approved Evoclin (clindamycin) Foam, 1% for the treatment of acne vulgaris. Evoclin (formerly referred to as Actiza™) is the first product approval for Connetics that is intended to address the acne market. A copy of the Connetics press release regarding Evoclin is attached as Exhibit 99.2 and is incorporated by reference in this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
| | | |
| Exhibit |
Number
| | Description
|
| 99.1 | | Press Release dated October 25, 2004, regarding Velac. |
| 99.2 | | Press Release dated October 25, 2004, regarding Evoclin. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | CONNETICS CORPORATION
| |
| | By: | /s/ Katrina J. Church | |
| | | Katrina J. Church | |
| | | Executive Vice President, General Counsel and Secretary | |
| |
Date: October 27, 2004
EXHIBIT INDEX
| | | |
| Exhibit |
Number
| | Description
|
| 99.1 | | Press Release issued October 25, 2004, regarding Velac. |
| 99.2 | | Press Release issued October 25, 2004, regarding Evoclin. |
